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Cytomegalovirus-associated superior mesenteric vein
thrombosis treated with systemic and in-situ thrombolysis
Wouter Van Moerkerckea, Karen Pauwelyna, Eddy Brugmanb
and Marc Verhammec
A 56-year-old patient, first diagnosed with an acute
cytomegalovirus infection, presented with progressive
abdominal pain because of a superior mesenteric vein
thrombosis for which he was treated with systemic
thrombolysis and heparin in continuous infusion. As this
therapy did not have the intended success after 5 days,
an interventional radiological procedure was performed
with local thrombolysis in the superior mesenteric artery
resulting in recanalisation of the vein. Oral anticoagulation
was initiated and continued for a period of 6 months.
Mesenteric venous thrombosis is a relatively uncommon
cause of mesenteric ischemia that can be associated with
severe morbidity and significant mortality. With noninvasive
techniques, it is possible to establish a diagnosis in the
majority of the cases. The importance of an early diagnosis
and therapy – not only with anticoagulation, but also
thrombolysis in selected cases – is shown with this case
and review of the literature. Eur J Gastroenterol Hepatol
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Introduction
Thrombosis of the (superior) mesenteric vein is a serious
event and had frequently been diagnosed in a chronic and
mostly irreversible state. Indeed, until recently, portal
vein (PV) thrombosis was generally recognized at a stage
of cavernous transformation complicated with portal
hypertension [1]. These days, a threshold to perform a
computed tomographic (CT) scan of the abdomen has
greatly diminished when a clinician is confronted with a
patient with abdominal pain without obvious etiology. As
a consequence, acute portomesenteric vein thrombosis
(PMVT) has been diagnosed more frequently, allowing
more efficient therapy such as thrombolysis.
A hypercoagulable state can be the result of a desequili-
brium between coagulation and fibrinolysis [2]. Both
congenital and acquired conditions, predisposing to
thrombosis, will be discussed. The concept of thrombosis
as a multifactorial process is highlighted. With this case
report, we first stress the importance of the role of an
acute cytomegalovirus (CMV) infection in the pathogen-
esis. More cases have been reported in the literature
worldwide [3–13]. On account of the rarity of reports
of CMV associated with venous thromboembolism in
general, it is assumed that CMV infection is a trigger
to thrombosis in the context of a predisposition to
thromboembolic disease [5]. Second, we discuss the
diagnostic and (more aggressive) therapeutic approach of
PMVT in general.
Case report
A 56-year-old immunocompetent male patient presented
with symtoms of fever up to 381C and persisting cough
since several days. Except for known hypertension and
hypercholesterolemia, he had a blank medical history.
Liver function tests were moderately disturbed, and CMV
IgM antibodies were detected. Screening for hepatitis and
HIV was negative. He was diagnosed as having an acute
CMV infection. Initial treatment was symptomatic and
consisted of adequate analgesia and antipyretics.
Ten days after discharge he was readmitted because of
anorexia and progressive abdominal pain with diffuse
tenderness at clinical examination. A contrast-enhanced
CT scan of the abdomen showed a thrombosis of the
superior mesenteric vein (SMV) (Fig. 1). Upon upper
endoscopic evaluation, no esophageal varices were
observed. A screening for thrombophilia (Table 1)
revealed the presence of anticardiolipin antibodies and
lupus anticoagulans. Janus kinase 2 mutation was
negative. In addition, a seroconversion with the appear-
ance of CMV IgG antibodies was confirmed 16 days after
the first admission with acute CMV infection.
Systemic thrombolysis with recombinant tissue plasmi-
nogen activator (rt-PA; a bolus of 10mg rt-PA with a
continuous infusion of 90mg in 2 h) did not have the
intended result. After this procedure, the abdominal pain
with tenderness mainly localized in the region of the
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mesogastrium, persisted with the same intensity.
A magnetic resonance angiography, performed 4 days
after systemic thrombolysis, showed no thrombotic
resolution. Subsequently, it was decided to inject a local
thrombolyticum in the superior mesenteric artery (SMA)
(Fig. 2a and b). A combination therapy consisting of
rt-PA (0.3mg/ml), with a total dose of 55mg, and heparin
(133 IU/ml) was initiated at an initial dose of
6ml/h (1.8mg rt-PA/h) and increased to 10ml/h (3mg
rt-PA/h). After starting a heparin infusion at 1000 IU/h
oral anticoagulation was associated. A CT relook
showed a patent SMV with complete resolution of the
thrombus (Fig. 3).
Discussion
Mesenteric vein thrombosis (MVT) was described as a
cause of intestinal ischemia in 1895 by Elliot [14]. Warren
and Eberhard differentiated venous thrombosis from
arterial thrombosis as a cause of intestinal infarction
[14–16]. In up to 95% of the cases, the SMV is affected.
Table 2 shows a summary of possible etiologies for MVT
[2,15,17–22]. Currently, it is possible to identify an
etiological factor in three-quarters of the patients [15].
When a clinician is confronted with a new diagnosis of
PMVT, one should exclude local factors such as
inflammatory processes (pancreatitis,y ), intra-abdom-
inal surgery, intra-abdominal neoplasm,y that can trigger
a PMVT (Table 2). In the section of systemic factors, we
use the concept of thrombophilia that can be either
congenital or acquired (for the latter, myeloproliferative
disorders, such as polycythemia vera and essential
thrombocythemia, are known risk factors). With the
evolution of better medical care, diagnostic imaging
studies, antibiotic treatment, and the better under-
standing of the coagulation system (in which the
importance of congenital disorders is obvious), there is
a shift in the profile of possible etiologies for
PMVT [20,22]. As mentioned before, thrombophilia
can be caused by congenital and acquired factors. In
the discussion of inherited thrombophilia (mutations
of factor V Leiden, protrombin, deficiencies of protein
C, S, and antitrombin III), it is important to know
that both a decreased hepatic synthesis of coagulation
factors and activation of coagulation (which is apparent
when a PMVT occurs) lead to a nonspecific decrease
of protein C, S, and antithrombin [2,15,19]. This makes
it more difficult to know if the deficiency is primary
or not.
Table 1 Results of screening for thrombophilia upon diagnosis
of the SMVT in the patient, as described in the case report
Result Reference Unit
CMV IgGa <4 0–6 IU/ml
CMV IgMa Positive Negative
Factor VIII 183 70–120 %
vWF 73 %
D-dimers 5110 0–500 mg/l
Antithrombin III 102 80–120 %
APC-resistance 121 >120 s
Protein C (Act) 108 70–140 %
Protein S (Act) 146 70–140 %
Anticardiolipin IgG 29.6 <10 GPL/ml
Anticardiolipin IgM 17.6 <10 MPL/ml
Lupus anticoagulans Positive
Homocystein 6.68 5–15 mmol/l
CMV IgGb 23 0–6 IU/ml
CMV IgMb Positive Negative
Factor V Leiden Wild type (no mutation)
Factor II G/A 20210 Wild type (no mutation)
Janus kinase 2 mutation Not present
Act, activated; APC, activated protein C; CMV, cytomegalovirus; SMVT, superior
mesenteric vein thrombosis; vWF, von Willebrand factor.
aOn day 1 (admission at the Service of Pneumology).
bOn day 16 (admission at the Service of Gastroenterology and Hepatology).
Fig. 1
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(a) (b)
Computer tomography of the abdomen upon admission of the patient, 16 days after the initial diagnosis of an acute cytomegalovirus infection,
showing thrombotic material in the superior mesenteric vein [arrow, (a)]. Reconstruction, showing the extent of the thrombus [arrow, (b)] to the
confluens of the splenic vein (SV) and superior mesenteric vein (SMV) with protrusion to the portal vein (PV).
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We handle a multifactorial concept in which a certain
trigger to thrombosis in a thrombophilic environment can
initiate a thrombotic event [23,24]. Frequently a personal
or family history of deep vein thrombosis or pulmonary
embolism is present [15,16]. When peripheral blood
results are normal, performing a bone marrow biopsy is
required in the screening for occult myeloproliferative
disorders. Recently, Janus kinase 2 mutation screening
has become a front-line diagnostic test in the evaluation
for occult myeloproliferative disorders when a PMVT is
present [23,25].
In this case report, we describe acute CMV infection as
another factor triggering portomesenteric thrombosis [3].
Studies with rats had shown a change in the production of
eicosanoids and increased procoagulant effects after
infection with CMV [26,27]. Several pathophysiological
mechanisms are assumed as an explanation for the
thrombophilia, mostly based on ‘in-vitro’ studies. First,
CMV has an endothelial cell tropism with damage of the
Fig. 2
(a) (b)
Angiography of the superior mesenteric artery at the moment of in-situ thrombolysis (a). Superior mesenteric vein (arrow) after in-situ thrombolysis (b).
Fig. 3
Complete recanalization (arrow) of the superior mesenteric vein.
Table 2 Overview of etiology of portomesenteric vein thrombosis
Systemic factors: thrombophilia
Inherited (congenital)
Mutation of factor V Leiden
Mutation of prothrombin (factor II)
Protein C and S deficiency
Antithrombin III deficiency
Acquired: myeloproliferative syndromes (polycythemia vera, essential
thrombocythemia); pregnancy, oral contraception, neoplasm,
antiphospholipid syndrome, infections (CMV),y
Local factors
Inflammation
Pancreatitis
Inflammatory bowel disease
Cholecystitis
Diverticulitis
Appendicitis
Peritonitis and intra-abdominal abscess
Intra-abdominal trauma
Abdominal surgery (e.g. splenectomy, colectomy, liver transplantation)
Neoplasm (e.g. pancreascarcinoma)
Cirrhosis with portal hypertension
Sclerotherapy for esophageal varices
Idiopathica
CMV, cytomegalovirus.
aTwenty percent (this percentage will further decrease with the discovery and
increasing knowledge of genetic thrombophilia and better diagnostic tools and
understanding such as the Janus kinase 2 mutation in screening for occult
myeloproliferative disorders).
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vascular endothelium [28]. An inflammated endothelium
shows a higher level of adhesion of circulating blood cells
[29,30]. A rearrangement of phospholipids in the cell
membrane after a CMV infection is responsible for a
facilitation of interaction with coagulation factors
[29–31]. Second, the adhesion of platelets and leukocytes
(leukotropism) is changed by a modulation of the
expression of adhesion molecules [intercellular adhesion
molecule, E-selectin,y ] [7]. Third, the synthesis of
lupus anticoagulans and factor VIII can be induced [8].
Antiphospholipid antibodies (anticardiolipin antibodies
and lupus coagulans) can appear after several infections
(e.g. viral infections such as CMV) and show an affinity
for anionic phospholipids [4,32]. Finally, a deficiency of
protein C (a natural anticoagulans) is possible after
infection with CMV, possibly because of consumption as
protein C has anti-inflammatory properties [8].
As mentioned, there is convincing ‘in-vitro’ evidence for
the procoagulant effect of CMV. In a more clinical context,
CMV is known to cause thrombotic events in patients with
an immunodeficient state such as infection with HIV or
immunosuppressive therapy [11,12]. Prospective studies
to investigate the exact role of CMV infection as a risk
factor for arterial and venous thrombosis and especially in
immunocompetent persons are needed. It is not known
why the entity of ‘PMVT’ is more frequent as the
topographic and typical clinical presentation of a primary
CMV infection complicated with thrombosis. Some reports
on deep vein thrombosis and secondary pulmonary
embolism are also observed [4,9–13]. In general, most
immunocompetent patients with a (primary) CMV infec-
tion have minimal or no symptoms. Typically, initial
therapy consists of antipyretics. Starting an antiviral
therapy is not indicated and if so, it is not clear what the
doses and duration of therapy should be.
In general, the clinical presentation of a PMVT depends
on the extent of the thrombus, the size of the affected
vessel, and the depth of bowel wall ischemia [15]. Two
compensatory mechanisms have a protective role for the
liver as a dual-vessel supplied organ. The first is the
‘arterial rescue’ in which arterial vasodilation occurs,
the second is the ‘venous rescue’ involving the rapid
development of a collateral venous network [2,19,23].
Extension to the splenic or PV is possible. Kumar and
Kamath [14] describe two entities: ‘large-vessel MVT’
(thrombosis of the SMV associated with thrombosis of the
splenic and/or PV) and ‘small-vessel MVT’ (thrombosis of
the smaller branches of the SMV). Less frequently, there
is bowel infarction in large-vessel MVT, but when it
occurs the extent of affected bowel is greater because of
extension of thrombus to venous arcades and vasa recta.
Patients can have acute onset of symptoms. An atypical
presentation with aspecific symptoms, such as abdominal
pain, vomiting, and sometimes bloody diarrhea as a sign of
intestinal ischemia, is also possible. An evolution to
peritonitis makes urgent laparatomy mandatory, other-
wise shock and death from multiple organ failure will
occur [33,34]. Complaints can also develop in a subacute
way (intra-abdominal discomfort for several days) or more
chronically (complications of portal hypertension, e.g.
variceal bleeding). It is important to know that up to 75%
of patients have had symptoms for more than 2 days
before medical care was searched [15,35]. Frequently, a
diagnosis is missed and made at the moment of doing a
laparotomy for acute abdomen or at autopsy [16,36].
Autopsy studies show the presence of superior MVT in
1.5% [16]. Several manners of medical imaging are
observed [37]. Thrombotic material can be visualized
with color Doppler ultrasonography. CT has a better
sensitivity and also shows affected intestines and
discloses other major intra-abdominal pathology such as
pancreatitis. The role of conventional angiography as a
gold standard for assessment of the splanchnic vascula-
ture is replaced by CT and MRI but remains superior for
demonstrating small mesenteric branch vessels [37].
The importance of a quick diagnosis and treatment must
be stressed as the risk of intestinal ischemia and
infarction increases with delay of treatment [33]. Second,
the chance for recanalization is optimized. Until now,
anticoagulation (heparin infusion, low molecular weight
heparins, and oral anticoagulation) was the gold standard
in the treatment of an acute PMVT. The absence of
clinical, endoscopic or radiological evidence of portal
hypertension is suggestive for the more recent onset of
the PMVT [22]. The aim is a maximal repermeation and
prevention of reoccurrence of thrombosis at short term.
Early anticoagulation for acute PMVT can achieve
complete or partial recanalization in 50 and 40% of
patients, respectively [1,16,18] Prevention of portal
hypertension at long term is fundamental, as esophageal
varices show a bleeding risk [22].
The use of a more aggressive approach can be defended
in certain cases, for example, in the presence of an
evolution to an acute abdomen as present in our case
[38]. This approach includes systemic thrombolysis on
the one hand and in-situ thrombolysis on the other. Local
instillation of a thrombolytic agent achieves high local
drug concentrations permitting efficient treatment [38].
On account of its fibrin specificity and more efficacious
dissolution of thrombi, rt-PA is more frequently used
[39–41]. In-situ administration is possible in a trans-
hepatic (retrograde) or transarterial (antegrade) way
[40,42,43]. In the latter approach the SMA is instillated
with a local thrombolyticum [43]. The bleeding risk is
less and the transarterial administration is preferred when
treating a MVT [38,44]. The transarterial infusion
enables the thrombolytic agent to permeate the capil-
590 European Journal of Gastroenterology & Hepatology 2009, Vol 21 No 5
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
laries and small venules [16,44]. In literature, the dose of
rt-PA is between 0.25 and 0.50mg/h [38]. In our case the
administered dose was higher, namely 1.8–3mg/h. It is
usually recommended to use intravenous heparin for at
least 24 h in maintaining vessel patency and preventing
reocclusion [41].
One could think that there is a possible greater bleeding
risk when anticoagulation or thrombolysis are initiated. In
a study from Condat and Valla, anticoagulant therapy in
84 out of 136 patients did not increase the risk or severity
of bleeding [19,45]. Repermeation prevents intestinal
ischemia in the short term and an evolution to portal
hypertension in the long term [19,45]. This outweighs
the associated risks and indicates a potential favorable
benefit–risk ratio for anticoagulation. In a retrospective
study of 20 patients receiving thrombolysis via the SMA
or the PV, the overall complication rate was 60% with
bleeding or decreased hematocrit level for which
transfusion was mandatory (in nine out of 20 patients);
but except for one patient – who died – the other eight
patients, for whom transfusion was necessary, improved.
In that study there was a complete recanalization in 15%,
partial result in 60%, and no effect in 25% [38].
Nevertheless, there are several limitations in the correct
interpretation as a control group (who did not receive
treatment or oral anticoagulation alone), limitations in
randomization, and uniformity of diagnosis and treatment
are lacking. Patients for which thrombolysis is initiated
more frequently have a severe pathology. For this reason a
prospective study in which a uniform strategy is present,
is mandatory.
Oral anticoagulation is not only useful in the treatment of
an acute thrombosis, but also in preventing recurrent
thrombosis [45]. The therapy is usually maintained for a
period of 6–12 months when a specific trigger is apparent
and when there is no evidence for a prothrombotic
disorder (i.e. underlying hypercoagulable state) for which
a lifelong therapy should be recommended [19]. The
optimal duration of anticoagulant therapy for prevention
of recurrent thrombosis in patients with antiphospholipid
antibodies is unknown. The decision regarding the
duration of anticoagulation can be influenced by the
type of antiphospholipid antibody (anticardiolipin anti-
body, lupus anticoagulans, or both) and a persisting
antibody response [46].
Although a surgical intervention is associated with a high
mortality because of a high number of reinterventions
and postoperative complications, a close clinical and
radiological follow-up is mandatory [38]. Surgery with
resection of nonviable intestinal tissue is an option in the
acute setting when there is evidence for underlying small
bowel infarction and if needed a second look laparatomy
can be necessary in reevaluation of the evolution at short
term as bowel infarction has a high mortality rate, up to
50% [15].
Conclusion
When confronted with a patient with a viral syndrome
and progressive abdominal pain because of MVT, it is
useful to look for a possible CMV infection as predispos-
ing factor to thrombosis as shown by several recent
publications. Inversely, the index of suspicion for MVT
when a patient with recent CMV infection develops
abdominal pain should be high.
Whatever the etiology of the acute persistent PMVT, we
emphasize and propose a more aggressive therapeutic
approach in an attempt to create a patent vessel as shown
in Discussion. Indeed, thrombolysis is indicated in
selected cases: for example, when extensive portomesen-
teric thrombosis, a severe symptomatology (e.g. acute
abdomen with signs of peritoneal tenderness), progres-
sion under anticoagulant therapy, or a clinical deteriora-
tion are present.
This is in contrast with only starting anticoagulation in
the more traditional approach in the treatment of a
PMVT. We also refer to thrombolysis as a well established
therapy in ischemic coronary and cerebral disease. Not
much information is available about the best choice of
thrombolyticum, the route of administration and the
duration of the therapy. The same problem exists for
therapy with oral anticoagulation. Clinical and prospec-
tive studies in determining guidelines for the treatment
of an acute PMVT are needed.
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